{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:32Z","timestamp":1772165672826,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Palivizumab has proven effective in reducing hospitalizations, preventing severe illness, improving health outcomes, and reducing healthcare costs for infants at risk of respiratory syncytial virus (RSV) infection. We aim to assess the value of palivizumab in preventing RSV infection in high-risk infants in Colombia, where RSV poses a significant threat, causing severe respiratory illness and hospitalizations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a decision tree analysis to compare five doses of palivizumab with no palivizumab. The study considered three population groups: preterm neonates (\u2264\u200935 weeks gestational age), infants with bronchopulmonary dysplasia (BPD), and infants with hemodynamically significant congenital heart disease (CHD). We obtained clinical efficacy data from IMpact-RSV and Cardiac Synagis trials, while we derived neonatal hospitalization risks from the SENTINEL-1 study. We based hospitalization and recurrent wheezing management costs on Colombian analyses and validated them by experts. We estimated incremental cost-effectiveness ratios and performed 1,000 Monte Carlo simulations for probabilistic sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Palivizumab is a dominant strategy for preventing RSV infection in preterm neonates and infants with BPD and CHD. Its high efficacy (78% in preventing RSV in preterm infants), the substantial risk of illness and hospitalization, and the high costs associated with hospitalization, particularly in neonatal intensive care settings, support this finding. The scatter plots and willingness-to-pay curves align with these results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Palivizumab is a cost-saving strategy in Colombia, effectively preventing RSV infection in preterm neonates and infants with BPD and CHD by reducing hospitalizations and lowering healthcare costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-024-09300-5","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T16:33:52Z","timestamp":1713544432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia"],"prefix":"10.1186","volume":"24","author":[{"given":"Jaime E.","family":"Ord\u00f3\u00f1ez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor M.","family":"Huertas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"issue":"3","key":"9300_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12016-013-8368-9","volume":"45","author":"AT Borchers","year":"2013","unstructured":"Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus\u2013a comprehensive review. Clin Rev Allergy Immunol. 2013;45(3):331\u201379.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"9300_CR2","first-page":"CD013757","volume":"11","author":"L Garegnani","year":"2021","unstructured":"Garegnani L, Styrmisd\u00f3ttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2021;11(11):CD013757.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3 Pt 1","key":"9300_CR3","first-page":"531","volume":"102","author":"Palivizumab","year":"1998","unstructured":"Palivizumab. A humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531\u20137.","journal-title":"Pediatrics"},{"issue":"5","key":"9300_CR4","doi-asserted-by":"publisher","first-page":"e20184064","DOI":"10.1542\/peds.2018-4064","volume":"143","author":"S Mac","year":"2019","unstructured":"Mac S, Sumner A, Duchesne-Belanger S, Stirling R, Tunis M, Sander B. Cost-effectiveness of Palivizumab for respiratory Syncytial Virus: a systematic review. Pediatrics. 2019;143(5):e20184064.","journal-title":"Pediatrics"},{"issue":"4","key":"9300_CR5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","volume":"143","author":"TF Feltes","year":"2003","unstructured":"Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Cardiac Synagis Study Group, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532\u201340.","journal-title":"J Pediatr"},{"key":"9300_CR6","volume-title":"Manual para la solicitud y emisi\u00f3n de conceptos sobre las evaluaciones de tecnolog\u00edas en salud realizadas por terceros","author":"IETS","year":"2021","unstructured":"IETS. Manual para la solicitud y emisi\u00f3n de conceptos sobre las evaluaciones de tecnolog\u00edas en salud realizadas por terceros. Bogot\u00e1 D.C.: Instituto de Evaluaci\u00f3n Tecnol\u00f3gica en Salud\u2013 IETS; 2021."},{"key":"9300_CR7","unstructured":"Banco de la Rep\u00fablica\u2013 Colombia. Total and per capita GDP at current prices. Available in https:\/\/www.banrep.gov.co\/en\/total-and-capita-gdp Consulted in February 2023."},{"issue":"4","key":"9300_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1055\/s-0039-1681014","volume":"37","author":"EJ Anderson","year":"2020","unstructured":"Anderson EJ, DeVincenzo JP, Sim\u00f5es EAF, Krilov LR, Forbes ML, et al. SENTINEL1: two-season study of respiratory Syncytial Virus hospitalizations among US infants born at 29 to 35 weeks\u2019 gestational age not receiving Immunoprophylaxis. Am J Perinatol. 2020;37(4):421\u20139.","journal-title":"Am J Perinatol"},{"key":"9300_CR9","doi-asserted-by":"crossref","unstructured":"Pi\u00f1eros JG, Baquero H, Bastidas J, Garc\u00eda J, Ovalle O, Pati\u00f1o CM, Restrepo JC. Respiratory syncytial virus infection as a cause of hospitalization in population under 1 year in Colombia. J Pediatr (Rio J). 2013 Nov-Dec;89(6):544\u20138.","DOI":"10.1016\/j.jped.2013.04.002"},{"issue":"1","key":"9300_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s41669-020-00218-7","volume":"5","author":"JA Buend\u00eda","year":"2021","unstructured":"Buend\u00eda JA, Pati\u00f1o DG. Costs of respiratory Syncytial Virus hospitalizations in Colombia. Pharmacoecon Open. 2021;5(1):71\u20136.","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"9300_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1164\/rccm.201609-1812OC","volume":"196","author":"H Mochizuki","year":"2017","unstructured":"Mochizuki H, Kusuda S, Okada K, Yoshihara S, Furuya H, Sim\u00f5es EAF. Scientific Committee for Elucidation of Infantile Asthma. Palivizumab Prophylaxis in Preterm neonates and subsequent recurrent wheezing. Six-year follow-up study. Am J Respir Crit Care Med. 2017;196(1):29\u201338.","journal-title":"Am J Respir Crit Care Med"},{"key":"9300_CR12","doi-asserted-by":"crossref","unstructured":"Rodriguez-Martinez CE, Sossa-Brice\u00f1o MP, Castro-Rodriguez JA. Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country. Allergol Immunopathol (Madr). 2020 Jan-Feb;48(1):56\u201361.","DOI":"10.1016\/j.aller.2019.04.004"},{"issue":"4","key":"9300_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1651-2227.2006.tb02252.x","volume":"95","author":"A Meberg","year":"2006","unstructured":"Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects\u2013hospitalizations and costs. Acta Paediatr. 2006;95(4):404\u20136.","journal-title":"Acta Paediatr"},{"issue":"1","key":"9300_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1089\/ped.2021.0143","volume":"35","author":"JA Buend\u00eda","year":"2022","unstructured":"Buend\u00eda JA, Guerrero Pati\u00f1o D, Giraldo Ram\u00edrez JE. Cost utility of intermittent inhaled corticosteroids in preschoolers with viral-triggered wheeze. Pediatr Allergy Immunol Pulmonol. 2022;35(1):36\u201342.","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"1","key":"9300_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/irv.12686","volume":"14","author":"D Hodgson","year":"2020","unstructured":"Hodgson D, Atkins KE, Baguelin M, Panovska-Griffiths J, Thorrington D, van Hoek AJ, et al. Estimates for quality of life loss due to respiratory Syncytial Virus. Influenza Other Respir Viruses. 2020;14(1):19\u201327.","journal-title":"Influenza Other Respir Viruses"},{"issue":"8","key":"9300_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/ppul.23073","volume":"50","author":"CE Rodriguez-Martinez","year":"2015","unstructured":"Rodriguez-Martinez CE, Nino G, Castro-Rodriguez JA. Cost-utility analysis of daily versus intermittent inhaled corticosteroids in mild-persistent asthma. Pediatr Pulmonol. 2015;50(8):735\u201346.","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"9300_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S2213-2600(18)30055-9","volume":"6","author":"NM Scheltema","year":"2018","unstructured":"Scheltema NM, Nibbelke EE, Pouw J, Blanken MO, Rovers MM, Naaktgeboren CA, et al. Respiratory syncytial virus prevention and asthma in healthy preterm neonates: a randomised controlled trial. Lancet Respir Med. 2018;6(4):257\u201364.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"9300_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/adc.2003.036129","volume":"89","author":"A Greenough","year":"2004","unstructured":"Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child. 2004;89(7):673\u20138.","journal-title":"Arch Dis Child"},{"issue":"11","key":"9300_CR19","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jval.2019.06.011","volume":"22","author":"T Shiri","year":"2019","unstructured":"Shiri T, Khan K, Keaney K, Mukherjee G, McCarthy ND, Petrou S. Pneumococcal disease: a Systematic Review of Health Utilities, Resource Use, costs, and economic evaluations of interventions. Value Health. 2019;22(11):1329\u201344.","journal-title":"Value Health"},{"issue":"36","key":"9300_CR20","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta12360","volume":"12","author":"D Wang","year":"2008","unstructured":"Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess. 2008;12(36):iii. ix-x.","journal-title":"Health Technol Assess"},{"issue":"4","key":"9300_CR21","doi-asserted-by":"publisher","first-page":"E615","DOI":"10.9778\/cmajo.20150051","volume":"4","author":"A Banerji","year":"2016","unstructured":"Banerji A, Panzov V, Young M, Robinson J, Lee B, Moraes T, et al. Hospital admissions for lower respiratory tract infections among infants in the Canadian Arctic: a cohort study. CMAJ Open. 2016;4(4):E615\u201322.","journal-title":"CMAJ Open"},{"issue":"3","key":"9300_CR22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/21645515.2016.1235670","volume":"13","author":"AA McGirr","year":"2017","unstructured":"McGirr AA, Schwartz KL, Allen U, Solomon M, Sander B. The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: a decision analysis model. Hum Vaccin Immunother. 2017;13(3):599\u2013606.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"9300_CR23","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/j.1651-2227.2011.02309.x","volume":"100","author":"K Neovius","year":"2011","unstructured":"Neovius K, Buesch K, Sandstr\u00f6m K, Neovius M. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden. Acta Paediatr. 2011;100(10):1306\u201314.","journal-title":"Acta Paediatr"},{"issue":"12","key":"9300_CR24","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1080\/13696998.2020.1836923","volume":"23","author":"O Narayan","year":"2020","unstructured":"Narayan O, Bentley A, Mowbray K, Hermansson M, Pivonka D, Kemadjou EN, Belsey J. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. J Med Econ. 2020;23(12):1640\u201352.","journal-title":"J Med Econ"},{"issue":"1","key":"9300_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00019053-200725010-00006","volume":"25","author":"MJ Nuijten","year":"2007","unstructured":"Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. PharmacoEconomics. 2007;25(1):55\u201371.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"9300_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10198-009-0206-x","volume":"11","author":"MJ Nuijten","year":"2010","unstructured":"Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ. 2010;11(1):105\u201315.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"9300_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3111\/13696990903316961","volume":"12","author":"M Nuijten","year":"2009","unstructured":"Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. J Med Econ. 2009;12(4):291\u2013300.","journal-title":"J Med Econ"},{"issue":"4","key":"9300_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3111\/13696990903347172","volume":"12","author":"M Nuijten","year":"2009","unstructured":"Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab in children with congenital heart disease in Germany. J Med Econ. 2009;12(4):301\u20138.","journal-title":"J Med Econ"},{"issue":"1","key":"9300_CR29","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/INF.0b013e318235455b","volume":"31","author":"B Resch","year":"2012","unstructured":"Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J. 2012;31(1):e1\u20138.","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"9300_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/adc.2008.155556","volume":"95","author":"E Rietveld","year":"2010","unstructured":"Rietveld E, Steyerberg EW, Polder JJ, Veeze HJ, Vergouwe Y, Huysman MW, de Groot R, Moll HA. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis. Arch Dis Child. 2010;95(7):493\u20138.","journal-title":"Arch Dis Child"},{"issue":"4","key":"9300_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00431-002-1106-6","volume":"162","author":"I Roeckl-Wiedmann","year":"2003","unstructured":"Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003;162(4):237\u201344.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"9300_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2191-1991-3-18","volume":"3","author":"A Bentley","year":"2013","unstructured":"Bentley A, Filipovic I, Gooch K, B\u00fcsch K. A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom. Health Econ Rev. 2013;3(1):18.","journal-title":"Health Econ Rev"},{"key":"9300_CR33","doi-asserted-by":"crossref","unstructured":"Salinas-Escudero G, Mart\u00ednez-Valverde S, Reyes-L\u00f3pez A, Gardu\u00f1o-Espinosa J, Mu\u00f1oz-Hern\u00e1ndez O, Granados-Garc\u00eda V, Rely K. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico. Salud Publica Mex. 2012 Jan-Feb;54(1):47\u201359.","DOI":"10.1590\/S0036-36342012000700010"},{"issue":"1","key":"9300_CR34","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1186\/s12879-017-2803-0","volume":"17","author":"M Sanchez-Luna","year":"2017","unstructured":"Sanchez-Luna M, Burgos-Pol R, Oyag\u00fcez I, Figueras-Aloy J, S\u00e1nchez-Sol\u00eds M, Martin\u00f3n-Torres F, Carbonell-Estrany X. Cost-utility analysis of Palivizumab for respiratory syncytial virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infect Dis. 2017;17(1):687.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"9300_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13561-017-0181-3","volume":"7","author":"R Schmidt","year":"2017","unstructured":"Schmidt R, Majer I, Garc\u00eda Rom\u00e1n N, Rivas Basterra A, Grubb E, Medrano L\u00f3pez C. Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain. Health Econ Rev. 2017;7(1):47.","journal-title":"Health Econ Rev"},{"issue":"4","key":"9300_CR36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3111\/13696998.2010.535577","volume":"13","author":"KA Smart","year":"2010","unstructured":"Smart KA, Paes BA, Lanct\u00f4t KL. Changing costs and the impact on RSV prophylaxis. J Med Econ. 2010;13(4):705\u20138.","journal-title":"J Med Econ"},{"issue":"4","key":"9300_CR37","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3111\/13696990903442155","volume":"12","author":"DY Tam","year":"2009","unstructured":"Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanct\u00f4t KL. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J Med Econ. 2009;12(4):361\u201370.","journal-title":"J Med Econ"},{"issue":"4","key":"9300_CR38","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1046\/j.1440-1754.2002.00790.x","volume":"38","author":"AM Vogel","year":"2002","unstructured":"Vogel AM, McKinlay MJ, Ashton T, Lennon DR, Harding JE, Pinnock R, Graham D, Grimwood K, Pattemore PK, Schousboe M. Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health. 2002;38(4):352\u20137.","journal-title":"J Paediatr Child Health"},{"issue":"5","key":"9300_CR39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3111\/13696998.2012.672942","volume":"15","author":"LB Weiner","year":"2012","unstructured":"Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ. Cost-effectiveness analysis of palivizumab among preterm infant populations covered by Medicaid in the United States. J Med Econ. 2012;15(5):997\u20131018.","journal-title":"J Med Econ"},{"issue":"6","key":"9300_CR40","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1542\/peds.2004-0224","volume":"114","author":"LE Yount","year":"2004","unstructured":"Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics. 2004;114(6):1606\u201311.","journal-title":"Pediatrics"},{"issue":"10","key":"9300_CR41","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/archpedi.160.10.1070","volume":"160","author":"NO Elhassan","year":"2006","unstructured":"Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006;160(10):1070\u20136.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"5","key":"9300_CR42","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta15050","volume":"15","author":"D Wang","year":"2011","unstructured":"Wang D, Bayliss S, Meads C. Palivizumab for Immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess. 2011;15(5):iii\u2013iv.","journal-title":"Health Technol Assess"},{"issue":"11","key":"9300_CR43","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0149-2918(00)83032-5","volume":"22","author":"JH Lofland","year":"2000","unstructured":"Lofland JH, O\u2019Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther. 2000;22(11):1357\u201369.","journal-title":"Clin Ther"},{"issue":"1","key":"9300_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00431-017-3046-1","volume":"177","author":"Blanken","year":"2018","unstructured":"Blanken MO, Frederix GW, Nibbelke EE, Koffijberg H, Sanders EAM, Dutch RSV Neonatal Network. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. Eur J Pediatr. 2018;177(1):133\u201344. Erratum in: Eur J Pediatr. 2020;179(2):355.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"9300_CR45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1824-7288-35-4","volume":"35","author":"G Chirico","year":"2009","unstructured":"Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital J Pediatr. 2009;35(1):4.","journal-title":"Ital J Pediatr"},{"issue":"6","key":"9300_CR46","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/archpediatrics.2010.298","volume":"165","author":"C Hampp","year":"2011","unstructured":"Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011;165(6):498\u2013505.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"9300_CR47","doi-asserted-by":"crossref","unstructured":"Harris KC, Anis AH, Crosby MC, Cender LM, Potts JE, Human DG. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective. Can J Cardiol. 2011 Jul-Aug;27(4):523.e11-5. English, French.","DOI":"10.1016\/j.cjca.2010.12.064"},{"issue":"12","key":"9300_CR48","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.arcped.2008.09.024","volume":"15","author":"JM Hascoet","year":"2008","unstructured":"Hascoet JM, Fagnani F, Charlemagne A, Vieux R, Roz\u00e9 JC, Bendjenana H. Aspects m\u00e9thodologiques de l\u2019\u00e9valuation \u00e9conomique du m\u00e9dicament en p\u00e9diatrie: Exemple De La Prophylaxie De L\u2019infection \u00e0 VRS en France [Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting]. Arch Pediatr. 2008;15(12):1739\u201348. French.","journal-title":"Arch Pediatr"},{"issue":"5","key":"9300_CR49","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3111\/13696998.2012.690013","volume":"15","author":"PJ Mahadevia","year":"2012","unstructured":"Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among preterm infants in the United States: a national policy perspective. J Med Econ. 2012;15(5):987\u201396.","journal-title":"J Med Econ"},{"issue":"3","key":"9300_CR50","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3111\/13696998.2010.499749","volume":"13","author":"KA Smart","year":"2010","unstructured":"Smart KA, Lanct\u00f4t KL, Paes BA. The cost effectiveness of palivizumab: a systematic review of the evidence. J Med Econ. 2010;13(3):453\u201363.","journal-title":"J Med Econ"},{"issue":"1","key":"9300_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3111\/13696998.2012.734886","volume":"16","author":"JM Hussman","year":"2013","unstructured":"Hussman JM, Lanct\u00f4t KL, Paes B. The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence. J Med Econ. 2013;16(1):115\u201324.","journal-title":"J Med Econ"},{"issue":"5","key":"9300_CR52","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/PCC.0b013e3182070990","volume":"12","author":"PA Checchia","year":"2011","unstructured":"Checchia PA, Nalysnyk L, Fernandes AW, Mahadevia PJ, Xu Y, Fahrbach K, Welliver RC, Sr. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011;12(5):580\u20138.","journal-title":"Pediatr Crit Care Med"},{"key":"9300_CR53","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1471-2334-9-106","volume":"9","author":"SK Morris","year":"2009","unstructured":"Morris SK, Dzolganovski B, Beyene J, Sung L. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis. 2009;9:106.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"9300_CR54","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40121-014-0046-6","volume":"3","author":"C Wegzyn","year":"2014","unstructured":"Wegzyn C, Toh LK, Notario G, Biguenet S, Unnebrink K, Park C, Makari D, Norton M. Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease due to respiratory syncytial virus infection: a systematic review. Infect Dis Ther. 2014;3(2):133\u201358.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"9300_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/17476348.2018.1401926","volume":"12","author":"SK Wong","year":"2018","unstructured":"Wong SK, Li A, Lanct\u00f4t KL, Paes B. Adherence and outcomes: a systematic review of palivizumab utilization. Expert Rev Respir Med. 2018;12(1):27\u201342.","journal-title":"Expert Rev Respir Med"},{"key":"9300_CR56","doi-asserted-by":"crossref","unstructured":"Gonzales T, Bergamasco A, Cristarella T, Goyer C, Wojdyla M, Oladapo A, Sawicky J, Yee J, Moride Y. Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review. Am J Perinatol. 2023 Jan 18.","DOI":"10.1055\/a-1990-2633"},{"issue":"8","key":"9300_CR57","first-page":"CD009834","volume":"8","author":"GB McCallum","year":"2017","unstructured":"McCallum GB, Plumb EJ, Morris PS, Chang AB. Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. Cochrane Database Syst Rev. 2017;8(8):CD009834.","journal-title":"Cochrane Database Syst Rev"},{"key":"9300_CR58","unstructured":"Global antimicrobial resistance and use surveillance system (GLASS) report. 2022. Geneva: World Health Organization; 2022. Available in https:\/\/www.who.int\/publications\/i\/item\/9789240062702 Consulted in February 2023."},{"key":"9300_CR59","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u2013655. Erratum in: Lancet. 2022;400(10358):1102."},{"key":"9300_CR60","volume-title":"Antimicrobial Resistance: tackling a Crisis for the Health and Wealth of nations","author":"Review on Antimicrobial Resistance","year":"2014","unstructured":"Review on Antimicrobial Resistance. Antimicrobial Resistance: tackling a Crisis for the Health and Wealth of nations. London: HM Government; 2014."},{"key":"9300_CR61","unstructured":"World Health Organization. Global Action Plan on Antimicrobial Resistance. 2015 [Internet] Available in https:\/\/www.who.int\/publications\/i\/item\/9789241509763 Consulted in February 2023."},{"issue":"4","key":"9300_CR62","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/ppul.23570","volume":"52","author":"RT Stein","year":"2017","unstructured":"Stein RT, Bont LJ, Zar H, Polack FP, Park C, Claxton A, Borok G, Butylkova Y, Wegzyn C. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol. 2017;52(4):556\u201369.","journal-title":"Pediatr Pulmonol"},{"issue":"10098","key":"9300_CR63","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","volume":"390","author":"T Shi","year":"2017","unstructured":"Shi T, McAllister DA, O\u2019Brien KL, Simoes EAF, Madhi SA, RSV Global Epidemiology Network, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946\u201358.","journal-title":"Lancet"},{"issue":"10340","key":"9300_CR64","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2022","unstructured":"Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, et al. RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047\u201364.","journal-title":"Lancet"},{"key":"9300_CR65","unstructured":"C\u00f3digo Sustantivo del Trabajo. Cap\u00edtulo V (Protecci\u00f3n A La Maternidad Y protecci\u00f3n de menores). Art\u00edculo 236. Descanso remunerado en la \u00e9poca del parto. Ministerio Del Trabajo. Gobierno de Colombia, Bogot\u00e1 D.C."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09300-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09300-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09300-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T17:01:34Z","timestamp":1713546094000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09300-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9300"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09300-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3077384\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]},"assertion":[{"value":"18 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is an economic evaluation, and all the data sources were secondary, so we did not require the approval of an Ethics Committee.No humans participated in this study, and we did not take data from medical records; we took all data from previously published studies. For this reason, we did not request informed consent, nor was the approval of an Ethics Committee requested.The study meets the publication criteria established in the CHEERS Statement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.This economic evaluation used secondary information sources and did not include human beings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"418"}}